Brivudine: potentially fatal toxicity of fluoropyrimidines if administered shortly before or at the same time with brivudine or used within 4 weeks after the end of treatment with brivudine

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Active substance
Brivudine
Procedure number
PSUSA/00000434/201907
Regulatory outcome
Variation
DHPC type
Periodic safety update single assessment
Human ATC code
J05AB15
Dissemination date
12/05/2020

How useful was this page?

Add your rating